Q-omics provides the consensus-scored VPS26A profile across patient tissues and cancer cell-line models. VPS26A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, VPS26A is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, VPS26A RNA expression shows 19,617 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where VPS26A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS26A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS26A survival associations across molecular data types. VPS26A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS26A RNA expression–survival associations across cancer types. High VPS26A expression shows unfavorable associations in HNSC, ACC, LIHC and PAAD, but favorable associations in KIRC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for VPS26A RNA expression.
This table summarizes VPS26A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS26A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS26A shows lower tumor expression in KICH and higher tumor expression in LIHC, CHOL, STAD, HNSC and LUAD. The LIHC box plot shows higher VPS26A RNA expression in tumor versus normal tissue (log2 FC = +1.074, t-test p < 0.001).
This table shows molecular features associated with VPS26A in patient tissues and cancer cell lines. In patient samples, VPS26A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS26A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
